Hepatocellular adenoma other diagnostic studies
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD[2]
Overview
The gold standard method for the diagnosis of hepatocellular adenoma is excision biopsy of liver lesions either by open surgery or laparoscopically. Percutaneous biopsy is not recommended due to the risk of bleeding and tumor dissemination. Other tests that can be used to differentiate between benign and carcinomatous lesions include QBend10 and erbB2 immunostaining, comparative genomic in situ hybridization, and fluorescence in situ hybridization.
Other Diagnostic Studies
- The gold standard test for the diagnosis of hepatocellular adenoma is excision biopsy of liver lesions either by open surgery or laparoscopically.[1]
- The microscopic differentiation between benign hepatic adenomas and hepatocellular carcinomas can be difficult, even with tumor tissue.
- Other diagnostic tests that can be used to differentiate benign and carcinomatous lesions include QBend10 and erbB2 immunostaining, comparative genomic in situ hybridization, and fluorescence in situ hybridization.[2][3][4][5]
- The percutaneous biopsy of hepatic lesions is not recommended due to the risk of bleeding and tumor dissemination.[6]
References
- ↑ N. Katkhouda, M. Hurwitz, J. Gugenheim, E. Mavor, R. J. Mason, D. J. Waldrep, R. T. Rivera, M. Chandra, G. M. Campos, S. Offerman, A. Trussler, P. Fabiani & J. Mouiel (1999). “Laparoscopic management of benign solid and cystic lesions of the liver”. Annals of surgery. 229 (4): 460–466. PMID 10203077. Unknown parameter
|month=ignored (help) - ↑ F. R. Scott, A. el-Refaie, L. More, P. J. Scheuer & A. P. Dhillon (1996). “Hepatocellular carcinoma arising in an adenoma: value of QBend 10 immunostaining in diagnosis of liver cell carcinoma”. Histopathology. 28 (5): 472–474. PMID 8735726. Unknown parameter
|month=ignored (help) - ↑ E. M. Brunt & P. E. Swanson (1992). “Immunoreactivity for c-erbB-2 oncopeptide in benign and malignant diseases of the liver”. American journal of clinical pathology. 97 (5 Suppl 1): S53–S61. PMID 1374219. Unknown parameter
|month=ignored (help) - ↑ L. Wilkens, M. Bredt, P. Flemming, T. Becker, J. Klempnauer & H. H. Kreipe (2001). “Differentiation of liver cell adenomas from well-differentiated hepatocellular carcinomas by comparative genomic hybridization”. The Journal of pathology. 193 (4): 476–482. doi:10.1002/path.825. PMID 11276006. Unknown parameter
|month=ignored (help) - ↑ L. Wilkens, M. Bredt, P. Flemming, Y. Schwarze, T. Becker, M. Mengel, R. von Wasielewski, J. Klempnauer & H. Kreipe (2001). “Diagnostic impact of fluorescence in situ hybridization in the differentiation of hepatocellular adenoma and well-differentiated hepatocellular carcinoma”. The Journal of molecular diagnostics : JMD. 3 (2): 68–73. doi:10.1016/S1525-1578(10)60654-X. PMID 11333302. Unknown parameter
|month=ignored (help) - ↑ Ludger Barthelmes & Iain S. Tait (2005). “Liver cell adenoma and liver cell adenomatosis”. HPB : the official journal of the International Hepato Pancreato Biliary Association. 7 (3): 186–196. doi:10.1080/13651820510028954. PMID 18333188.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH